Presbyopia

A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

Panel discusses the highs and lows of treating patients with this condition.

Considering safety and efficacy of new drops and the potential impact on your patients.

Sean W. Smolenyak, OD, gives a brief overview of presbyopia, including the cause and available treatments.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

Erin Rueff, OD, PhD, FAAO, shares highlights from her 2022 American Academy of Optometry presentations in the contact lens space.

Presbyopia-correcting drops for patients with low, up-close visual function.

Evolution of vision correction procedures, diagnostics paves way for collaborative care.

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

Experts answer clinicians’ common questions on treating patients.

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Michelle Hoff, OD, FAAO, ABOM, FNAO, and Isabel Kazemi, OD, FAAO, share key takeaways from their VEW 2022 presentation, "Demystifying near-task specific lenses."

Expert advice offers key practice management tips for making presbyopia drops an integrated part of a clinical armamentarium.

Help presbyopia patients by following fitting guides and embracing new adjunct therapy options.

Patients present with a plethora of complaints, with blurred near vision, headache, fatigue, need for increased working distance and brighter light to read among the most common, according to Cecelia Koetting, OD, during AOA 2022.

Bobby Saenz, OD, MS, FAAO, discusses his AOA 2022 presentation, "Extended Depth of Focus Lenses and Drops."

A pharmaceutical approach (pilocarpine hydrochloride ophthalmic solution 1.25% ) to improving near vision can be used with other technology, benefiting a wide variety of patients.

Companies are entering an exclusive licensing agreement for the development and commercialization of Brimochol PF and Carbachol PF in three new regions: Greater China, South Korea, and select Southeast Asian territories.

Advice for pilots to consider ahead of taking flight.

A look at the current and future landscape of treatment options for this age-related condition.

Trial data finds that CSF-1 (pilocarpine hydrochloride 0.4%), a preservative-free ophthalmic solution, met both its primary and secondary endpoints.

Study evaluated twice-daily administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in adults with age-related blurry near Vision

There will be very little downside to optometrists and their practice in offering presbyopia-correcting drops to patients who want better vision without glasses or contact lenses.

Presbyopia awareness: Causes, risk factors, symptoms, correction options and market trends.

With advanced, easy-to-fit multifocal lens technologies, patients don’t need to compromise

The latest launches of BRIO-I and BRIO-II follow promising topline data from the phase 2 VIVD clinical study evaluating Brimochol PF.

CSF-1 is a preservative-free solution designed as an alternative to reading glasses for patients.